AAAAAA

   
Results: 1-7 |
Results: 7
Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100
Authors: Hatse, S Princen, K Gerlach, LO Bridger, G Henson, G De Clercq, E Schwartz, TW Schols, D
Citation: S. Hatse et al., Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100, MOLEC PHARM, 60(1), 2001, pp. 164-173
AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice
Authors: Matthys, P Hatse, S Vermeire, K Wuyts, A Bridger, G Henson, GW De Clercq, E Billiau, A Schols, D
Citation: P. Matthys et al., AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice, J IMMUNOL, 167(8), 2001, pp. 4686-4692
Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
Authors: Hendrix, CW Flexner, C MacFarland, RT Giandomenico, C Fuchs, EJ Redpath, E Bridger, G Henson, GW
Citation: Cw. Hendrix et al., Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers, ANTIM AG CH, 44(6), 2000, pp. 1667-1673
The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis
Authors: Blanco, J Barretina, J Henson, G Bridger, G De Clercq, E Clotet, B Este, JA
Citation: J. Blanco et al., The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis, ANTIM AG CH, 44(1), 2000, pp. 51-56
Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA
Authors: Van Gelder, J Witvrouw, M Pannecouque, C Henson, G Bridger, G Naesens, L De Clercq, E Annaert, P Shafiee, M Van den Mooter, G Kinget, R Augustijns, P
Citation: J. Van Gelder et al., Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA, INT J PHARM, 186(2), 1999, pp. 127-136
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor
Authors: Este, JA Cabrera, C De Clercq, E Struyf, S Van Damme, J Bridger, G Skerlj, RT Abrams, MJ Henson, G Gutierrez, A Clotet, B Schols, D
Citation: Ja. Este et al., Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor, MOLEC PHARM, 55(1), 1999, pp. 67-73
Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4
Authors: Este, JA Cabrera, C Blanco, J Gutierrez, A Bridger, G Henson, G Clotet, B Schols, D De Clercq, E
Citation: Ja. Este et al., Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4, J VIROLOGY, 73(7), 1999, pp. 5577-5585
Risultati: 1-7 |